The Src/PI3K/Akt signal pathway may play a key role in decreased drug efficacy in obesity-associated cancer
✍ Scribed by Jiezhong Chen
- Publisher
- John Wiley and Sons
- Year
- 2010
- Tongue
- English
- Weight
- 40 KB
- Volume
- 110
- Category
- Article
- ISSN
- 0730-2312
No coin nor oath required. For personal study only.
✦ Synopsis
O besity not only results in increased incidence but also leads to poor prognosis of many cancers. The increased cancer incidence in obesity is accounted for by the activation of cellular signal pathways which are carcinogenic such as Src/PI3K/Akt pathway [Chen, 2008; Huang and Chen, 2009b]. However, the mechanism for the poor prognosis in obesity-associated cancer is still unclear. It is an urgent issue required to be solved so that the treatment of obesity-associated cancer can be improved. A possible explanation is that the poor prognosis in obesity-associated cancer is caused by decreased drug efficacy due to the activation of multiple cellular signal pathways. Among these pathways the Src/PI3K/Akt may play a critical role. It is well demonstrated that the Src/PI3K/Akt pathway is activated by multiple cancer risk factors in obesity, while the activation of the pathway has also been shown to associate with decreased drug efficacy. Thus, it will be interesting to further demonstrate the critical role of the pathway in decreased drug efficacy caused by obesity and confirm that the activation of the pathway has lead to poor prognosis in obesity-associated cancer.